MedTrace Logo

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-04-15

No results posted yet for this study

Summary

The primary objective of this protocol is to examine \[18F\]MNI-1126 as a tool to assess synaptic density loss.

Conditions

  • Alzheimer Disease
  • Parkinson Disease
  • Healthy Volunteers

Interventions

DRUG

[18F]MNI-1126

Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures. DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures.

Sponsors & Collaborators

  • Invicro

    lead OTHER

Principal Investigators

  • David Russell, M.D., Ph. D · Invicro

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2020-02-26
Completion
2020-02-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03587649 on ClinicalTrials.gov